QLine Biotech IPO
QLine Biotech IPO Details
-
Open Date
21 May 2026
-
Close Date
25 May 2026
- IPO Price Range
₹ 326 to ₹343
- IPO Size
₹ 214.48 Cr
QLine Biotech IPO Timeline
QLine Biotech IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 21-May-2026 | 4.15 | 5.26 | 3.71 | 4.17 |
| 22-May-2026 | 5.19 | 15.62 | 10.07 | 9.87 |
| 25-May-2026 | 123.94 | 145.98 | 71.44 | 102.42 |
Last Updated: 25 May 2026 6:46 PM by 5paisa
Q-Line Biotech Ltd. develops, manufactures and markets a broad range of reagents, diagnostic kits, point-of-care devices and consumables, alongside importing and distributing diagnostic equipment. Since 2013, the company has supplied IVD products and pathology equipment to diagnostic service providers, hospitals and medical colleges, directly and through distributors. Its key manufacturing segments include Clinical Chemistry, Haematology, Immunodiagnostics and Molecular Diagnostics. As of 31 December 2025, its annual manufacturing capacity stood at approximately 1.4 million kits and 1,200 Selectra machines.
Established in: 2010
Managing Director: Mr. Saurabh Garg.
QLine Biotech Objectives
1. To meet working capital requirements (₹93.50Cr)
2. Repayment of certain borrowing availed by the Company, in part or full (₹90.00Cr)
3. General Corporate Purposes
Q-Line Biotec IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹214.48 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹214.48 Cr |
Q-Line Biotec IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 800 | 2,60,800 |
| Retail (Max) | 2 | 800 | 2,74,400 |
| S - HNI (Min) | 3 | 1,200 | 3,91,200 |
| S - HNI (Max) | 7 | 2,800 | 9,60,400 |
| B - HNI (Min) | 8 | 3,200 | 10,43,200 |
Q-Line Biotec IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 123.94 | 11,88,000 | 14,72,37,200 | 5,050.24 |
| Non-Institutional Buyers | 145.98 | 8,91,600 | 13,01,53,600 | 4,464.27 |
| BNII | 178.29 | 5,94,400 | 10,59,76,000 | 3,634.98 |
| SNII | 81.35 | 2,97,200 | 2,41,77,600 | 829.29 |
| Individual Investors (IND category bidding for 2 Lots) | 71.44 | 20,79,200 | 14,85,32,800 | 5,094.68 |
| Total** | 102.42 | 41,58,800 | 42,59,23,600 | 14,609.18 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 182.74 | 203.65 | 313.78 |
| EBITDA | 32.98 | 37.63 | 71.32 |
| PAT | 32.10 | 34.45 | 28.13 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 251.58 | 339.25 | 455.49 |
| Share Capital | 1.58 | 1.58 | 1.58 |
| Total Liabilities | 251.58 | 339.25 | 455.49 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 24.97 | -24.18 | -1.32 |
| Net Cash Generated From / (used in) Investing Activities | -26.31 | -44.69 | -59.09 |
| Net Cash Generated From / (used in) Financing Activities | 26.40 | 16.99 | 53.34 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 25.06 | -52.88 | -7.07 |
Strengths
1. Diverse portfolio across multiple diagnostic healthcare segments
2. Strong indigenous manufacturing capabilities for diagnostic reagents
3. Established distribution network serving hospitals and laboratories
4. Consistent production capacity supporting growing healthcare demand
Weaknesses
1. Heavy dependence on domestic diagnostic healthcare market
2. Limited global brand recognition against multinational competitors
3. Capital-intensive manufacturing operations affecting profitability margins
4. Dependence on distributors for wider market penetration
Opportunities
1. Rising demand for affordable diagnostic healthcare solutions
2. Expansion potential within emerging international healthcare markets
3. Increasing adoption of molecular diagnostic testing technologies
4. Government support for indigenous medical equipment manufacturing
Threats
1. Intense competition from established global diagnostic companies
2. Regulatory compliance changes impacting manufacturing and distribution
3. Rapid technological advancements requiring continuous product innovation
4. Supply chain disruptions affecting raw material availability
1. Diversified diagnostic portfolio across multiple healthcare segments
2. Strong manufacturing capabilities supporting long-term business expansion
3. Growing demand for affordable diagnostic healthcare solutions
4. Experienced presence within India’s expanding diagnostics industry
Q-Line Biotec operates in the rapidly expanding diagnostics and in-vitro diagnostics (IVD) industry, driven by increasing healthcare awareness, rising chronic disease prevalence and growing demand for affordable diagnostic solutions. The company’s diversified product portfolio, indigenous manufacturing capabilities and established distribution network position it well for future growth. Increasing adoption of molecular diagnostics, government support for domestic medical manufacturing and expansion opportunities in emerging healthcare markets could further strengthen Q-Line Biotec’s long-term business prospects and revenue growth potential.
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Q-Line Biotec IPO opens from May 21, 2026 to May 25, 2026.
The size of Q-Line Biotec IPO is ₹214.48 Cr.
The price band of Q-Line Biotec IPO is fixed at ₹326 to ₹343 per share.
To apply for Q-Line Biotec IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Q-Line Biotec. IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Q-Line Biotec IPO is of 800 shares and the investment required is ₹2,60,800.
The share allotment date of Q-Line Biotec IPO is May 26,2026
The Q-Line Biotec IPO will likely be listed on May 29, 2026.
Hem Securities Ltd is the book running lead managers for Q-Line Biotec IPO.
Q-Line Biotec IPO plans to utilise the raised capital from the IPO for:
1. To meet working capital requirements (₹93.50Cr)
2. Repayment of certain borrowing availed by the Company, in part or full (₹90.00Cr)
3. General Corporate Purposes